Step 1 of 2
Metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) are closely linked with obesity and cardiometabolic disease, creating opportunities for earlier identification and more comprehensive management. In this downloadable slideset, expert faculty review the shared pathophysiology connecting obesity, liver health, and cardiovascular risk, along with current recommendations for risk assessment, fibrosis screening, and patient stratification. Learners will also explore the latest evidence supporting obesity-directed and MASH-directed therapies, including incretin-based treatments, resmetirom, and emerging investigational agents, and examine strategies for multidisciplinary care across the disease continuum.